Stoke Therapeutics

Stories

First treatment targeting the genetic root of Dravet syndrome shows dramatic seizure reduction

As of May 2026: Developer of zorevunersen; leading the Phase 3 EMPEROR trial

Dravet syndrome is a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a 15–20 percent mortality rate. For nearly five decades, no treatment addressed the underlying cause — including two drugs approved in the past eight years, which could only partially suppress symptoms.

Updated May 30